Welcome, Guest. Please login or register.
November 20, 2017, 06:22:54 PM

Login with username, password and session length

  • Total Members: 31856
  • Latest: esm
  • Total Posts: 722532
  • Total Topics: 58715
  • Online Today: 351
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: GSK Halts Development of PI Brecanavir  (Read 2146 times)

0 Members and 1 Guest are viewing this topic.

Offline Tim Horn

  • Member
  • Posts: 799
GSK Halts Development of PI Brecanavir
« on: December 19, 2006, 11:40:07 AM »

GSK Halts Development of PI Brecanavir

By Tim Horn, Senior Writer & Editor, AIDSmeds.com

GlaxoSmithKline (GSK) announced on December 18 that it has discontinued development of brecanavir, its experimental protease inhibitor, due to "insurmountable" problems developing a formulation for the drug.

Early studies, including a 24-week Phase II study, indicated that brecanavir held promise for HIV-positive people either starting therapy for the first time or those with virus resistant to other protease inhibitors.

According to a press release issued by GSK, the decision to halt development of brecanavir was based on the company's inability to develop a viable oral dosage formulation capable of delivering the desired drug levels in treatment-experienced patients.

"As in all of our drug development programs," the press release said, "GSK investigated several formulations of brecanavir. We conducted extensive studies in an effort to identify a formulation that would maximize therapeutic benefit for people living with HIV, especially those who are heavily treatment-experienced. Ultimately, our formulation work could not overcome the limitations of the brecanavir molecule which make consistent delivery of target drug levels unachievable."

GSK is in the process of notifying researchers associated with clinical trials of brecanavir. HIV-positive patients receiving brecanavir through these studies will be taken off the drug and directed to an approved HIV option or another experimental agent, if necessary.




Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.